Dynamic hyperinflation impairs daily life activity in asthma
- PMID: 30679190
- DOI: 10.1183/13993003.01500-2018
Dynamic hyperinflation impairs daily life activity in asthma
Abstract
Introduction: Dynamic hyperinflation has been documented in asthma, yet its impact on overall health and daily life activities is unclear. We assessed the prevalence of dynamic hyperinflation in moderate to severe asthma and its relationship with the scores of a set of specific and general respiratory health questionnaires.
Methods: 77 nonsmoking asthma patients (Global Initiative for Asthma steps 4-5) were recruited consecutively and completed five questionnaires: Asthma Control Questionnaire, Clinical COPD (chronic obstructive pulmonary disease) Questionnaire, St George's Respiratory Questionnaire, London Chest Activity of Daily Living scale (LCADL) and Shortness of Breath with Daily Activities (SOBDA). Dynamic hyperinflation was defined as ≥10% reduction in inspiratory capacity induced by standardised metronome-paced tachypnoea. Associations between level of dynamic hyperinflation and questionnaire scores were assessed and adjusted for asthma severity.
Results: 81% (95% CI 71.7-89.4%) of patients showed dynamic hyperinflation. Higher levels of dynamic hyperinflation were related to poorer scores on all questionnaires (r=0.228-0.385, p<0.05). After adjustment for asthma severity, dynamic hyperinflation remained associated with poorer scores on LCADL (p=0.027) and SOBDA (p=0.031).
Conclusion: Dynamic hyperinflation is associated with poorer overall health and impaired daily life activities, independent of asthma severity. Because of its major impact on everyday life activities, dynamic hyperinflation is an important target for treatment in asthma.
Copyright ©ERS 2019.
Conflict of interest statement
Conflict of interest: A-N. van der Meer reports grants from Medical Centre Leeuwarden Research Fund, TEVA, GSK and Stichting Longgeneeskunde Fryslan, during the conduct of the study. Conflict of interest: K. de Jong has nothing to disclose. Conflict of interest: A. Hoekstra-Kuik has nothing to disclose. Conflict of interest: E.H. Bel reports grants and/or personal fees from Novartis, GSK, Sanofi Regenron, Roche, AstraZeneca, Teva, Veactira and Boehringer, outside the submitted work. Conflict of interest: A. ten Brinke reports grants from Medical Centre Leeuwarden Research Fund, TEVA, GSK and Stichting Longgeneeskunde Fryslan, during the conduct of the study; institutional fees for research advisory board work from GSK, Sanofi, TEVA, AstraZeneca and Boehringer Ingelheim, and institutional fees for lecturing from GSK, TEVA and AstraZeneca, outside the submitted work.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical